Patents Assigned to GlaxoSmithKline
-
Patent number: 11786467Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.Type: GrantFiled: December 22, 2021Date of Patent: October 17, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Patent number: 11786924Abstract: Aspects of the present invention are directed to a variable dose container. The variable dose container may comprise a container including a top portion, a bottom portion, and a side wall portion, the space between the bottom portion and the side wall portion defining an interior space, wherein the container stores contents within the interior space. The variable dose container may further include an actuator coupled with the top portion of the container that is depressible in a longitudinal direction to drive the contents held in the interior space of the container out of a nozzle protruding horizontally from the actuator. Additionally, the variable dose container may include a collar under the nozzle, a top circumferential edge of the collar containing one or more grooves of varying depth into which the nozzle can be inserted when depressed, thereby adjusting a distance the actuator is moved in the longitudinal direction.Type: GrantFiled: September 20, 2019Date of Patent: October 17, 2023Assignee: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLCInventors: Amit Sabherwal, Gregory Ornoski
-
Publication number: 20230321132Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: ApplicationFiled: June 13, 2023Publication date: October 12, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Publication number: 20230321213Abstract: The present invention relates to the field of neisserial vaccine compositions (particularly gonococcal vaccine compositions) and the use of such compositions in medicine. More particularly, the present invention relates to genetically modified gonococci of strain FA1090 and outer membrane vesicles obtained therefrom. The invention also provides a process for preparing the genetically modified gonococci of the invention as well as immunogenic compositions and vaccines comprising the outer membrane vesicles of the invention.Type: ApplicationFiled: September 9, 2021Publication date: October 12, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Isabel DELANY, Giulia GIORDANO, Rosanna LEUZZI, Immaculada MARGARIT Y ROS
-
Patent number: 11780885Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: GrantFiled: November 15, 2017Date of Patent: October 10, 2023Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Kimberly Dowd, Barney S. Graham, Sung-Youl Ko, Wing-Pui Kong, John Mascola, Theodore Pierson, Mayuri Sharma, Dong Yu
-
Patent number: 11773139Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.Type: GrantFiled: December 14, 2018Date of Patent: October 3, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Stefania Capone, Antonella Folgori, Armin Lahm, Benjamin Wizel
-
Patent number: 11773078Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.Type: GrantFiled: May 10, 2019Date of Patent: October 3, 2023Assignee: Glaxosmithkline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
-
Patent number: 11773395Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: October 3, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Publication number: 20230303637Abstract: Polypeptides capable of self-assembling into a nanoparticle, and nanoparticles made up of such polypeptides.Type: ApplicationFiled: June 11, 2021Publication date: September 28, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Matthew James BOTTOMLEY, Newton Muchugu WAHOME
-
Patent number: 11766401Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.Type: GrantFiled: December 22, 2021Date of Patent: September 26, 2023Assignee: GlaxoSmithKline Biologicals SAInventor: Andrew Geall
-
Publication number: 20230295313Abstract: The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL 1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL 1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease.Type: ApplicationFiled: June 22, 2020Publication date: September 21, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: John G. Emery, Qi Fei, Shiyong Gong, Sanjay Kumar, Fang Ren, Teddy Yang, Hua Ying
-
Patent number: 11759422Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.Type: GrantFiled: April 1, 2020Date of Patent: September 19, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Ayush Verma
-
Patent number: 11759475Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: September 19, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Publication number: 20230277657Abstract: A microfluidic mixing device (101) comprising: a mixing chamber; one inlet channel (104) into the mixing chamber (102) for a first fluid and two inlet channels (103a, 103b) into the mixing chamber for a second fluid, said inlet channels being disposed substantially symmetrically at a proximal end (108) of the mixing chamber; at least one outlet (105) for mixed material at a distal end of the mixing chamber, wherein the mixing chamber comprises one or more baffles.Type: ApplicationFiled: May 4, 2021Publication date: September 7, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Philippe Raymond JEHOULET, Amedeo MENAFRO, Laurent STRODIOT, Emanuele TOMBA, Ioannis TSOUMPAS
-
Publication number: 20230279106Abstract: The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.Type: ApplicationFiled: September 2, 2022Publication date: September 7, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Yan Y. DEGENHARDT, Jun GUAN, Kenneth William HANCE, Peter Joseph MORLEY
-
Patent number: 11744890Abstract: Crude aqueous extracts of Quillaja saponaria Molina containing at least the QS-21 main peak and 2018 component, wherein the ratio of 2018 component/QS-21 main peak is ?0.075, as measured by UV absorbance at 214 nm, methods for obtaining such extracts and related aspects.Type: GrantFiled: November 30, 2018Date of Patent: September 5, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Ahmad Taimour Baig, Juan Jose Diaz Garcia, Chad Austin Farrenburg, Kent Raymond Myers, Jeri Kay Sandvick, Jeb Yeatts Vandenburg
-
Publication number: 20230272000Abstract: Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.Type: ApplicationFiled: January 19, 2023Publication date: August 31, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ahmad Taimour BAIG, Felicie Georgette, Colette DENET, Juan Jose DIAZ GARCIA, Chad Austin FARRENBURG, Lora Lea LAWRENCE, Kent Raymond MYERS, Jeri Kay SANDVICK, Jeb Yeatts VANDENBURG
-
Patent number: 11739334Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: August 29, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Publication number: 20230266317Abstract: The present invention relates to in vitro assays, more particularly ELISA assays. Said ELISA assays comprise antibodies capable of binding Ubiquitous surface protein A2 (UspA2) from Moraxella catarrhalis. The present invention relates to assays for assessing the binding of antibodies to UspA2 and the relative potency of vaccine test samples comprising UspA2. In particular, the invention relates to in vitro relative potency assays used in the release of vaccine that comprises UspA2 to the public.Type: ApplicationFiled: September 9, 2020Publication date: August 24, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Michael CHAPLET, Nathalie NORAIS, Simona RONDINI, Silvia ROSSI PACCANI
-
Patent number: 11730754Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: August 22, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl